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A B S T R A C T
Background
Cystic fibrosis is a genetically inherited, life-threatening condition that affects major organs. The management of cystic fibrosis involves
a multi-faceted daily treatment regimen that includes airway clearance techniques, pancreatic enzymes and other medications. Previous
studies have found that compliance with this intensive treatment is poor, especially among adolescents. Because of both the nature
and consequences of the illness and the relentless demands of the treatment, many individuals with cystic fibrosis have a poor quality
of life. Anecdotal reports suggest that singing may provide both appropriate exercise for the whole respiratory system and a means of
emotional expression which may enhance quality of life.
Objectives
To evaluate the effects of singing as an adjunct therapy to standard treatment on the quality of life, morbidity, respiratory muscle
strength and pulmonary function of children and adults with cystic fibrosis.
Search methods
We searched the Group’s Cystic Fibrosis Trials Register and the Cochrane Central Register of Controlled Trials. Date of latest search:
31 March 2014.
We also searched major allied complementary data bases, and clinical trial registers. Additionally, we handsearched relevant conference
proceedings and journals. Date of latest search: 24 May 2012.
Selection criteria
Randomised controlled trials in which singing (as an adjunct intervention) is compared with either a control intervention (for example,
playing computer games or doing craft activities) or no singing in people with cystic fibrosis.
Data collection and analysis
Results of searches were reviewed against pre-determined criteria for inclusion. Only one eligible trial was available for analysis.
1Singing as an adjunct therapy for children and adults with cystic fibrosis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
Since only one small study was included, nometa-analysis could be performed. The included study was a parallel, randomised controlled
trial undertaken at two paediatric hospitals in Australia. The study evaluated the effects of a singing program on the quality of life
and respiratory muscle strength of hospitalised children with cystic fibrosis (mean age 11.6 years, 35% male). While the singing group
received eight individual singing sessions, the control group participated in preferred recreational activities, such as playing computer
games or watching movies. This study was limited by a small sample size (51 participants) and a high drop-out rate (21%).
There were no significant differences between the groups at either post-intervention or follow up; although by the end of treatment
there were some within-group statistically significant increases for both singing and control groups in some of the domains of the quality
of life questionnaire Cystic Fibrosis Questionnaire-Revised (e.g. emotional, social and vitality domains). For the respiratory muscle
strength indices, maximal expiratory pressure at follow up (six to eight weeks post-intervention) was higher in the singing group, mean
difference 25.80 (95% confidence interval 5.94 to 45.66). There was no significant difference between groups for any of the other
respiratory function parameters (maximal inspiratory pressure, spirometry) at either post-intervention or follow up.
Authors’ conclusions
There is insufficient evidence to determine the effects of singing on quality of life or on the respiratory parameters in people with cystic
fibrosis. However, there is growing interest in non-medical treatments for cystic fibrosis and researchers may wish to investigate the
impact of this inexpensive therapy on respiratory function and psychosocial well-being further in the future.
P L A I N L A N G U A G E S U M M A R Y
The effects of singing on lung function and quality of life in children and adults with cystic fibrosis
People with cystic fibrosis are at risk of chest infections due to abnormally thick mucus in their airways. Airway clearance is therefore
an important part of cystic fibrosis management. Increasing anecdotal reports suggests that singing may support lung function and
enhance quality of life in people with cystic fibrosis. We searched for trials using the standard search methods of the Cochrane Cystic
Fibrosis and Genetic Disorders Group, and conducted extensive searches in other relevant databases and publications.
One small study evaluated the effects of singing on the quality of life and lung function of children with cystic fibrosis who are in
hospital. This study compared singing with other non-physical leisure activities, such as playing computer games or watching movies.
The included study was limited by the small number of participants (only 51 participants) and a high drop-out rate (21%). The study
assessed the impacts of singing on respiratory muscle strength, quality of life and lung function tests. It found a statistically significant
difference in maximal expiratory pressure (a substitute measure of respiratory muscle strength) in favour of singing at one time point.
However, both the singing and control groups showed improvements in some quality of life measurements; and no differences were
reported in other lung function measures. There is currently not enough evidence to show that singing can improve clinical outcomes
in people with cystic fibrosis. Future studies using robust methods are needed to assess the possible effects of singing for people with
cystic fibrosis.
B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is a genetically inherited life-threatening con-
dition that affects major organs, such as the lungs, pancreas, liver
and kidneys. Individuals with CF produce abnormally excessive
thick mucus in the airways, which makes them more susceptible
to lung diseases. Repeated infections in the airways lead to irre-
versible lung damage (Phelan 1994).
The management of CF involves a multifaceted daily treatment
regimen that usually includes airway clearance techniques, phys-
ical exercise, pancreatic enzymes and other medications, as well
as hospital admissions. Such an intensive treatment regimen may
have a negative psychosocial impact on children and adolescents
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(Glasscoe 2008), particularly on adolescents (D’Auria 2000). Pre-
vious studies have found that individuals with CF may have poor
quality of life (QoL) (Quittner 2008).
Description of the intervention
For individuals with CF, the respiratory muscles play an important
role in maintaining lung health (Reid 2008; Sawyer 1993). Respi-
ratory muscle strength is vital for airway clearance techniques, as it
helps to generate effective cough to expectorate secretion (Chang
2006; Widdicombe 2006). Respiratory muscle function also af-
fects exercise capacity in people with CF (Enright 2004), and
greater levels of exercise capacity are correlated with lower levels of
mortality (Nixon 1992). To improve respiratory muscle function
in CF, conventional treatment uses inspiratory muscle training
(IMT)devices. Some research has shown that an IMTprogramcan
improve respiratory muscle function in children (Sawyer 1993);
however, a recent systematic review detected only weak evidence
that conventional IMT devices were beneficial (Reid 2008). Using
an IMT device can also be seen as another chore for individuals
with CF, given the complexity of the daily treatment regimen. In
contrast, a singing intervention may provide an enjoyable activity
which would also have therapeutic benefits.
The dome-shaped diaphragm is a primary inspiratory muscle, and
separates the thorax from the abdomen (Titze 1994). The di-
aphragm flattens as it contracts, and expands the thorax, thus in-
creasing air intake by increasing lung volume (Leanderson 1987;
Leanderson 1988). Sundberg found that singing requires greater
use of vital lung capacity than normal speech, due to the longer
phrases contained in songs (Sundberg 1987). Singers, therefore,
need to use their lung capacity efficiently in order to sustain long
phrases while singing. Classical singers use almost 100% of their
vital lung capacity at the beginning of long phrases, so that ex-
tra breaths are not necessary (Sundberg 1987). Although not all
trained singers use identical breathing behaviours, opera singers
have been found to have highly consistent breathing strategy and
greater movement of the rib cage and abdomen while singing
(Thomasson 1999).
Anecdotal reports suggest that singing may be beneficial for people
with chronic respiratory diseases (Elliott 2009; NHS Choices
2011; Stacy 2002).
Current literature suggests that singing interventions based on
diaphragmatic breathing can improve or maintain the respiratory
muscle functions in people with chronic obstructive pulmonary
disease (COPD) (Bonilha 2009), multiple sclerosis (Wiens 1999)
and Parkinson’s disease (Di Benedetto 2009). In these studies, the
respiratory muscle strength (using maximal inspiratory pressure
(MIP) and maximal expiratory pressure (MEP)) were measured as
the indicators reflecting changes in the respiratory muscle strength
attributed to the singing intervention.
Singing can also reduce fear, anxiety and pain perception and im-
prove mood (Kenny 2004; Unwin 2002). Further, singing can
provide not only health benefits but also enjoyment. Studies found
thatwhen singing ormusicwere part of a breathing exercise, partic-
ipants with asthma demonstrated better treatment compliance due
to greater enjoyment, which enhanced their motivation (Fukuda
2000; Lipawen 2000).
Additionally, a number of anecdotal reports attest to the benefits
of singing in enhancing the quality of life (QoL) of people with
chronic lung diseases (Stacy 2002). Studies investigating the effects
of a singing or music program on the lung health and QoL of
people with COPD (Bonilha 2009; Lord 2010), emphysema (
Engen 2005) and asthma (Wade 2002) indicate that singing can be
an enjoyable, low-cost and low-risk intervention, which supports
lung health and enhances QoL.
How the intervention might work
Studies show that singing requires a regulation of exhaled air flow
and promotes the use of vital capacity to the fullest possible ex-
tent (Collyer 2009; Sundberg 1987). Similar to other airway clear-
ance techniques, such as the active cycle of breathing technique
(Robinson 2010), singing promotes good posture (relaxed neck
and shoulders), control of breathing, and thoracic expansion. Fur-
thermore, singing does not require a device or an assistant, and
can provide some necessary enjoyment to reduce treatment bur-
den and reinforce further training (Raskin 2009).
A singing intervention can be carried out in a one-to-one or in
a group setting, and should be conducted in a non-judgmental
and supportive environment. The program needs to be of suffi-
cient length and intensity to allow participants to master the di-
aphragmatic breathing technique. This can vary from individual
to individual, depending on their age, background, illness severity,
past experience with singing and music as well as the relationship
between the singing facilitator and the patient. A study of peo-
ple with emphysema (over 60 years of age) indicated that at least
two half-hour sessions are necessary for participants to learn the
diaphragmatic breathing method correctly (Engen 2005).
Why it is important to do this review
A recent Cochrane systematic review identified very few research
studies on non-medical interventions in the field of CF (Glasscoe
2008). Despite progress in medical treatment for CF, psycholog-
ical therapies to improve emotional well-being have been limited
(Elgudin 2004). To date, CF treatment has been dominated by
rigorous medical treatments. Although essential, this may also re-
flect a disease-oriented view, in which only the physical symptoms
are treated. A single medical treatment may be unable to provide
the care and management required to improve all aspects of QoL
in people living with CF. A multidisciplinary treatment regimen
may be effective in meeting the complex needs of individuals with
CF. Research in health psychology supports this view and provides
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strong evidence that numerous factors influence both illness and
well-being (Bernard 1994; Knight 1998). These should be taken
into account when providing a health service which aims to opti-
mise both medical and psycho-social health outcomes.
Singing is a relatively inexpensive adjunct intervention which can
potentially enhance QoL and provide enjoyable and effective ex-
ercise for the respiratory system of people with CF.
This is an update of a previous version of this review (Irons 2010).
O B J E C T I V E S
To evaluate the effects of singing as an adjunct therapy to stan-
dard treatment on QoL, respiratory muscle strength, pulmonary
function and morbidity of children and adults with CF.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised controlled trials.
Types of participants
People with CF, of any age, diagnosed on the basis of sweat testing
or genotype analysis.
Types of interventions
All types of singing intervention that included diaphragmatic
breathing, which were carried out in a group or one-to-one set-
ting, facilitated by singing instructors or teachers, voice coaches
or trainers, or music therapists, for a minimum of two half-hour
sessions. Studies comparing singing with a control group that did
not involve the activation of the respiratory muscles were to be
considered (for example, playing computer games or doing craft
activities). Studies using non face-to-face delivery format, such
as DVD or CD were not considered as these formats could not
address some important issues such as how to use the voice in a
healthy way while singing, and to obtain immediate feedback on
singing practice, posture and breathing technique. Further, indi-
vidual or group singing sessions can also be adjusted to the levels
of singers, which is hard to achieve through media, such as DVD
or CD.
Types of outcome measures
Primary outcomes
1. QoL measured by validated instruments, e.g. Cystic
Fibrosis Questionnaire-Revised (CFQ-R) (Quittner 2009), St.
George’s Respiratory Questionnaire (Jones 1991), Pediatric
Quality of Life InventoryT M (PedsQLT M ) (Varni 1999)
2. Respiratory muscle function
i) maximal inspiratory pressure (MIP)
ii) maximal expiratory pressure (MEP)
iii) cough peak flow (Table 1)
Secondary outcomes
1. Other subjective scores (e.g. cough diary using Likert scales
or visual analogue scales (Table 1) measuring subjective
assessment of interference of cough)
2. Spirometry
i) forced expiratory volume in one second (FEV1)
ii) forced vital capacity (FVC)
iii) forced mid-expiratory flow rate (FEF25−75%)
3. Number of participants experiencing adverse effects (e.g.
coughing up blood and difficulty in breathing)
4. Respiratory exacerbations
i) total number of hospitalised days
ii) total number of symptomatic days
iii) number of participants with respiratory exacerbations
5. Adherence to other CF treatments (e.g. measured by a
diary, self-evaluation checklist)
6. Psychological assessments measuring self-efficacy,
depression and anxiety
Search methods for identification of studies
There were no language or publication restrictions.
Electronic searches
We searched theGroup’s Cystic Fibrosis Trials Register for relevant
trials using the terms: ’cystic fibrosis’ AND ’singing’.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of The Cochrane Library),
quarterly searches of MEDLINE, a search of Embase to 1995
and the prospective handsearching of two journals - Pediatric Pul-
monology and the Journal of Cystic Fibrosis. Unpublished work is
identified by searching the abstract books of three major cystic
fibrosis conferences: the International Cystic Fibrosis Conference;
the European Cystic Fibrosis Conference and theNorth American
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Cystic Fibrosis Conference. For full details of all searching activi-
ties for the register, please see the relevant sections of the Cystic
Fibrosis and Genetic Disorders Group Module.
Date of search: 31 March 2014.
We also searched the following sources; please see the appendices
for details of search terms and dates:
• Allied and Complementary Database AMED (1985 to
2012) (Appendix 1);
• PsycINFO (1872 to 2012) (Appendix 2);
• CINAHL (all years to present) (Appendix 3);
• Dissertation Abstracts International (late 1960 to 2012)
(Appendix 4);
• www.clinicaltrials.gov (all years to 2012) (Appendix 5);
• Music therapy research database (all years to 24/09/2009)
(Appendix 6);
• National Research Register (NRR) Archive (2000 to 2012)
(Appendix 7).
Note: the Music Therapy Research Database has been inactive so
there was no new search for the 2012 update.
Searching other resources
We searched other relevant publications, including hand searching
of music or singing or music therapy journals.
Journal Date searched
Nordic Journal of Music Therapy (2003 - 2012; Vol 21 (Issue 1)) 24/05/2012
Australian Journal of Music Therapy (1996 - 2011; Vol 22) 24/05/2012
The New Zealand Journal of Music Therapy (1987 - 2012) 24/05/2012
The British Journal of Music therapy (1987 - 2011) 24/05/2012
Musiktherapeutische Umschau (GermanMusic Therapy Journal)
(2000 - 2011)
24/05/2012
Further, we have contacted experts (singing or music therapy-
related researchers and singing facilitators or teachers) in this area
and on receipt of written communication from the authors of
trials, would have included these in the review as necessary.
Data collection and analysis
Selection of studies
Twoauthors (JYI, AC) independently assessed studies for inclusion
in the review based on the inclusion criteria stated above. If there
was any disagreement in this process, they would have consulted
with the third author (DK) and resolved by discussion.
Data extraction and management
Two authors (JYI, AC) independently extracted data from the
eligible study on to a standard data extraction form. One author
(JYI) entered the data into RevMan for analysis (RevMan 2011)
and AC checked the entered data.
The authors reviewed the study that satisfied the inclusion cri-
teria and recorded the following information: study setting, year
of study, source of funding, participants recruitment details (in-
cluding number of eligible people), inclusion and exclusion crite-
ria, other symptoms, randomisation and allocation concealment
method, numbers of participants randomised, blinding (masking)
of participants, care providers and outcome assessors, duration of
intervention, previous singing training, co-interventions, numbers
of participants not followedup, reasons forwithdrawals from study
protocol (clinical, side-effects, refusal and other), details on side-
effects of therapy, and whether intention-to-treat analyses were
conducted. The authors extracted data on the outcomes described
previously at three points: short term (at less than one month),
medium term (over one month and up to six months), and longer
term (over six months and up to one year and annually thereafter).
If in future updates of this review, the authors include further stud-
ies and if necessary, they planned to contact the study authors for
any missing information.
In a post hoc change, the authors considered that reporting the
differences (change scores) from baseline to post-intervention or
follow up, or both, in the outcome measures to be appropriate in
this review.
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Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of the
included study using the ’Risk of Bias’ tool as described in Chapter
8 of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
Generation of the allocation sequence
The authors assessed the study for the generation of allocation
sequence as follows:
1. low risk of bias, if methods of randomisation include using
a random number table, computer-generated lists or similar
methods;
2. unclear risk of bias, if the trial was described as randomised,
but no description of the methods used to allocate participants
to treatment group was described;
3. high risk of bias, if methods of randomisation include
alternation, the use of case record numbers, dates of birth or day
of the week, and any procedure that was entirely transparent
before allocation.
Allocation concealment
The authors assessedwhether allocationwas adequately concealed,
to prevent both participants and investigators from foreseeing as-
signment:
1. low risk of bias, if the allocation of participants involved a
central independent unit, on-site locked computer, identically
appearing numbered drug bottles or containers prepared by an
independent pharmacist or investigator, or sealed opaque
envelopes;
2. unclear risk of bias, if the method used to conceal the
allocation was not described;
3. high risk of bias, if the allocation sequence was known to
the investigators who assigned participants, for example it was
based on day of admission or case record number.
Blinding (or masking)
Due to the nature of the intervention, it is impossible to blind
participants. The authors assessed the included study as towhether
the outcome assessors were blinded to treatment allocation (low
risk of bias); unclear whether they were blinded (unclear risk of
bias); or not blinded to treatment (high risk of bias).
Follow up
The authors graded the study as to whether numbers of and rea-
sons for dropouts and withdrawals in all intervention groups were
described; or whether it was specified that there were no dropouts
or withdrawals:
1. low risk of bias, if reasons for dropouts and withdrawals
described;
2. unclear risk of bias, if insufficient or selective reporting of
dropouts and withdrawals;
3. high risk of bias, if not reporting reasons for dropouts and
withdrawals likely to be related to true outcome.
Selective outcome reporting
The authors tried to identify and report on any selective reporting
in the included study, by comparing the study protocol with the
final published paper. If in future the authors include further stud-
ies, for which the protocols are not available, the authors will com-
pare the ’Methods’ and ’Results’ sections of the published study.
Authors will make risk of bias judgements as follows:
1. low risk of bias, if all outcomes reported as being measured
were reported;
2. unclear risk of bias, if it was unclear whether all measured
outcomes were reported;
3. high risk of bias, if not all outcomes that were measured
were reported.
Other potential sources of bias
The authors tried to identify any other sources of bias not reported
elsewhere in the review and assessed their potential for putting the
study results at risk of bias.
Measures of treatment effect
If the authors had identified more than one study, they would
have undertaken an initial qualitative comparison of all the in-
dividually analysed studies to examine whether pooling of results
(meta-analysis) was reasonable. This would have taken into ac-
count differences in study populations, inclusion and exclusion
criteria, interventions and outcome assessment. The results from
studies that met the inclusion criteria and that report any of the
outcomes of interest would have been included in the subsequent
meta-analyses.
For the dichotomous outcome variables of each individual study,
the authors planned to calculate the odds ratio (OR) and 95%
confidence intervals (CIs) using intention to treat analysis. The au-
thors used the Cochrane statistical package RevMan 5.1 (RevMan
2011). If the authors include more studies in future, they will cal-
culate the numbers needed to treat (NNT) from the pooled OR
and its 95% CI applied to a specified baseline risk (from the con-
trol group) using an online calculator (Cates 2003).
For continuous outcomes, the authors calculated the mean dif-
ference (MD) and 95% CIs using RevMan 5.1 (RevMan 2011)
using ’as treated’ approach. If, in future, studies report outcomes
using different measurement scales, the authors will calculate the
standardised mean difference.
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Unit of analysis issues
Cross-over trials are not appropriate for this intervention and thus
the authors planned to only include data from the first arm of any
cross-over studies.
Dealing with missing data
The authors would have requested further information from the
primary investigators where appropriate.
Assessment of heterogeneity
If more than one study were available, the authors planned to
describe heterogeneity between the study results and test this to see
if it reached statistical significance using the chi2 test. The authors
would have considered heterogeneity to be significant if the P value
was less than 0.10 (Higgins 2011). The authors also planned to
present the I² statistic, which quantifies the inconsistency of the
results of the studies as described in Chapter 9 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
and would have defined heterogeneity as low if less than 25%,
moderate if the value was between 25% and 75%, and high if the
value was over 75% (Higgins 2003).
Assessment of reporting biases
If the combination of data and a meta-analysis (with at least 10
studies) had been possible, the authors would have assessed pub-
lication bias using a funnel plot.
Data synthesis
The authors calculated the summary OR and mean differences
with 95% CIs using a fixed-effect model. They would have used
a random-effects model if they had concerns about statistical het-
erogeneity, i.e. when there was at least moderate heterogeneity as
defined above using the I² statistic, where I² is at least 50%.
The authors planned only to combine ’Other subjective scores’
(see Secondary outcomes), if they deemed it clinically appropriate.
Subgroup analysis and investigation of heterogeneity
If the authors had been able to include sufficient studies in the
review and it was appropriate, they planned the following a priori
sub-group analyses:
1. children (under 18 years old) versus adults;
2. severity of CF (based on FEV1% predicted, where over
80% is classified as mild; 50% to 79% is classified as moderate;
30% to 49% is classified as severe; and less than 30% is classified
as very severe);
3. type of singing intervention (e.g. individual or group
singing, length of follow up);
4. intervention conducted during an acute exacerbation versus
stable state.
Sensitivity analysis
The authors also planned sensitivity analyses to assess the impact
of the potentially important factors on the overall outcomes, if
there were sufficient studies (n = 10):
1. variation in the inclusion criteria (e.g. studies conducted
during exacerbations versus stable state, duration of
intervention);
2. risk of bias in the included studies (selection, performance,
detection, attrition and reporting bias);
3. analysis using random-effects model (to assess
heterogeneity).
R E S U L T S
Description of studies
Results of the search
Two authors (JYI and AC) undertook initial screening of the ab-
stracts of these studies. Since the 2009 review, an additional 156
potential studies were identified; a total of 17 papers were reviewed
for detailed assessment. Of these, none fulfilled the inclusion cri-
teria; hence in the current review four studies are listed in the
Characteristics of excluded studies table. The Irons study, previ-
ously listed as ongoing in the original review, has since been com-
pleted, and been added as the sole included study (Irons 2012). A
study flow diagram is shown in the figures (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
The included study was a dual-centre (both in Australia), parallel,
randomised controlled study, which included hospitalised chil-
dren and adolescents (aged 7 to 17 years) with a pulmonary exac-
erbation (Irons 2012). A total of 51 young people were randomly
assigned to either a singing group or a control group participating
in non-physical recreational activities. The singing group partic-
ipated in eight individual singing lessons during hospitalisation
over a period of approximately two weeks; these lessons consisted
of:
1. exercises to develop the desired posture for singing;
2. diaphragmatic breathing exercises;
3. vocal warm-ups; and
4. singing using the diaphragmatic technique.
Children in the control group participated in their preferred non-
physical recreational activities (e.g. playing computer games or
watching movies) for the same period of time. Outcome measures
included CFQ-R (QoL), MIP,MEP and spirometry (FEV1, FVC,
FEF25−75%). These were reported at post-intervention (approxi-
mately two weeks from baseline) and follow up (six to eight weeks
post-intervention). In addition, for the post-intervention period
a singing diary, which consisted of six simple daily tasks for six
weeks, was given to the participants in the singing group only in
order to encourage their singing activities at home. The partici-
pants of the control group were encouraged to perform their usual
CF management at home.
Only 40 participants (20 for each group) were included in analysis
at post-intervention and 30 (15 for each group) at follow up.
Excluded studies
A total of four studies were excluded (Grasso 2000; Kaak 2011;
Reichardt 2011; Roux 2007). One music therapy study used pre-
recorded music as an adjunct to regular chest physiotherapy for
toddlers withCF (under 24months old) and their caregivers; how-
ever, singing was not explored in this study (Grasso 2000). An-
other study investigated the effects of listening to Bach’s Magni-
ficat (a religious choral work) on 40 adults with pneumonia or
acute bronchitis; again singing (as opposed to listening to music)
was not part of the intervention in this study (Roux 2007). Two
further studies, both in German, were excluded: one investigated
the effects of playing the didgeridoo (as opposed to singing) with
people with CF (Kaak 2011); and the remaining study reported
the benefits of a singing program (Hustifex® - Brummer®) based
on observations; however the program was designed for patients
with chronic obstructive pulmonary disease andnotCF (Reichardt
2011).
Risk of bias in included studies
An overview of our judgement of the risk of bias in the included
study is presented in the figures (Figure 2).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The randomisation sequence was computer-generated by a person
external to the study; thus there is a low risk of bias (Irons 2012).
Allocation was concealed by using opaque stickers on a randomi-
sation list, and again the risk of bias is low (Irons 2012).
Blinding
Due to the nature of intervention, blinding was not possible for
either patients or clinicians, leading to a high risk of bias. In addi-
tion, the researcher who collected theQoL data was not blinded to
the intervention allocation, leading to a high risk of bias for these
outcomes. However, the respiratory scientists who collected data
for all lung function tests were blinded to participants’ allocation.
This factor gave a low risk of bias due to blinding for outcome
assessors for these outcomes (Irons 2012).
Incomplete outcome data
The attrition rate was high, which may represent a bias; however,
there were similar dropout rates in both groups (Irons 2012). The
authors judged there to be an high risk of bias for this domain.
Selective reporting
The study was considered at low risk of bias for reporting bias.
The study reported all outcomes according to their protocol in
line with the record on the Australian New Zealand Clinical Trials
Registry. The authors also reported all time-points (baseline, post-
intervention, follow up) as planned (Irons 2012).
Other potential sources of bias
There may have been a selection bias, as people with a previous
positive experience of singing may have been more likely to agree
to enrol in a singing study (high risk of bias).
The paper did not report the sample size calculation. Study au-
thors reported that the calculation was based on power of 90% (at
5% significance) for a MD (standard deviation (SD)) of 10 (10)
cm H2O in MIP between groups (Irons 2012). This estimated a
required sample size of 23 participants per group.
Effects of interventions
Primary outcomes
1. QoL
There were no significant differences between the two groups at
either post-intervention or follow up. Although there were some
within-group statistically significant increases in some domains for
treatment and control groups (e.g. emotional, social and vitality)
between baseline and post-intervention assessment, as presented
in the additional tables (Table 2).
Investigators assessed QoL using the CFQ-R questionnaire which
has 12 different domains, some of which apply only for adoles-
cents (from 14 years of age) (Quittner 2009). The data from 40
participants in these 12 domains were partially skewed, and thus
non-parametric tests (Wilcoxon signed-rank) were performed for
the original analysis. We present medians and IQR at baseline,
post-intervention and follow up in the additional tables (Table 2),
since it would be inappropriate to analyse themeans and SDof the
QoL data from the included study (Irons 2012). Post-intervention
assessment took place after eight sessions (i.e. on average, between
10 and 14 days from baseline). Follow-up assessment took place
six to eight weeks after the post-intervention time-point. There
were 40 participants included in the analysis from baseline to post-
intervention, while 30 were included for follow-up analysis. Four
domains (vitality, health perception, role and weight) apply only
for adolescents (between14 and 17 years of age). For these do-
mains, data from six adolescents from each group were included
for the post-intervention analysis and from five adolescents for the
follow-up analysis.
2. Respiratory muscle function
a. MIP
There were no statistically significant differences between the
singing and control groups at either post-intervention, MD 6.00
(95% CI -1.67 to 13.67); or follow up, MD 4.40 (95% CI -9.36
to 18.16) (Analysis 1.1).
b. MEP
There were no statistically significant differences between the
singing and control groups at post-intervention, MD 3.05 (95%
CI -12.43 to 18.53). However, statistical significance in the mean
difference was detected at follow up favouring the singing group,
MD 25.80 (95% CI 5.94 to 45.66) (Analysis 1.2).
c. Cough peak flow
This outcome was not reported.
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Secondary outcomes
1. Other subjective scores
Other subjective scores (e.g. cough diary using Likert scales or vi-
sual analogue scales measuring subjective assessment of interfer-
ence of cough) were not reported.
2. Spirometry
a. FEV1
There were no statistically significant differences between the two
groups at either post-intervention, MD -0.04 (95% CI -0.20 to
0.11); or follow up, MD -0.15 (95% CI -0.36 to 0.06) (Analysis
2.1).
b. FVC
There were no statistically significant differences between the two
groups at either post-intervention, MD -0.10 (95% CI -0.25 to
0.06); or follow up, MD -0.11 (95% CI -0.29 to 0.07) (Analysis
2.2).
c. FEF25−75%
There were no statistically significant differences between the two
groups at either post-intervention, MD -0.03 (95% CI -0.39 to
0.33); or follow up, MD -0.29 (95% CI -0.81 to 0.24) (Analysis
2.3).
3. Number of participants experiencing adverse effects
Irons reported that no adverse effects were observed in the singing
group; adverse events for the control group were not reported in
the paper.
4. Respiratory exacerbations
a. total number of hospitalised days
This outcome was not reported.
b. total number of symptomatic days
This outcome was not reported.
c. number of participants with respiratory exacerbations
This outcome was not reported.
6. Adherence to other CF treatments
This outcome was not reported.
7. Psychological assessments measuring self-efficacy,
depression and anxiety
This outcome was not reported.
D I S C U S S I O N
Summary of main results
In this update, only one small study conducted by three of the
review authors has been included (Irons 2012). At follow up, a sta-
tistically significant improvement in MEP favouring the singing
group was found, MD 25.80 (95% CI 5.94 to 45.66); however
there were no differences in other lung function parameters and
both groups experienced improvements in a number of QoL do-
mains. At follow up, only the singing group continued with any
form of the intervention; although singing sessions did not con-
tinue as they had in the hospital, participants were asked to keep
a diary of six simple singing tasks for six to eight weeks following
hospital discharge.
Overall completeness and applicability of
evidence
There is insufficient evidence to make a judgement on the efficacy
of singing for people with CF. The single included study was lim-
ited by the small sample size, high attrition rate and the limited
applicability of MIP andMEP (Irons 2012). There is no guideline
on the minimal clinically important difference in MIP and MEP
for children and adolescents with CF; and the normal range of
MIP and MEP is reported to be wide (Domenech-Clar 2003).
Therefore, the result should be interpreted with caution.
Quality of the evidence
The quality of the evidence is currently low due to the small sam-
ple size, high attrition rate of participants and the non-blinded
assessment of QoL measures.
Potential biases in the review process
The authors sought to limit potential biases through extensive
searches and attempts to identify all relevant studies. As already
declared in the protocol, authors of the included study are also
authors of this review.
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Agreements and disagreements with other
studies or reviews
The results of the included study (Irons 2012)were similar to those
of previous singing studies in other chronic respiratory conditions
(Bonilha 2009; Lord 2010), in multiple sclerosis (MS) (Wiens
1999) and in Parkinson’s Disease (Di Benedetto 2009). While CF
is a different condition to these other chronic illnesses, there are
similarities with regard to the disease impact on QoL, the char-
acteristics of the obstructive lung disease, the respiratory symp-
toms (difficulty in breathing, breathlessness), and the nature of the
chronic conditions. For example, patients with chronic obstruc-
tive pulmonary disorder (COPD) demonstrated increased respira-
tory muscle strength measured by MEP (mean change from base-
line to post-intervention 3.0 H2O cm; P = 0.05) after 24 weekly
singing sessions (Bonilha 2009). Another study in patients with
COPD found that 12 bi-weekly group singing sessions reduced
anxiety and depression and enhanced general well-being (Lord
2010). Also, a 12-week singing intervention in patients with MS
improved MEP (mean change from baseline to post-intervention
2.8 H2O cm; P > 0.05) (Wiens 1999), and a 13-week singing pro-
gram in people with Parkinson’s Disease helped to improve MIP
(mean change from baseline to post-intervention 7.4H2Ocm; P =
0.02) and MEP (mean change from baseline to post-intervention
21 H2O cm; P = 0.01) (Di Benedetto 2009).
The included study demonstrated a mean (SD) improvement of
12.1 (7.8) H2O cm in MIP scores from baseline to post-interven-
tion in the singing group; the mean (SD) increase of 6.1 (14.5)
H2O cm seen in the control arm was less, but the difference be-
tween groups was not statistically significant (Irons 2012). Nev-
erthless, the increase in MIP in the included study was a greater
improvement than in other studies on singing as an intervention
(Bonilha 2009; Di Benedetto 2009; Wiens 1999), although the
numbers cannot be compared directly given the differences be-
tween other conditions (COPD, Parkinson’s Disease andMS) and
CF. The magnitude of the increase in MIP in the Irons study is
similar to that seen with a conventional inspiratory muscle train-
ing method for 10 weeks during a stable period, a study of which
reported an increase in mean MIP post-intervention of 14 H2O
cm (Sawyer 1993).
In relation to the QoL results from the Irons study, participants in
both the singing and control groups showed similar improvements
in respiratory symptoms and treatment burden domains at post-
intervention (Irons 2012). Only the singing group continued to
have a reduced treatment burden at follow up as they had contin-
ued their singing activities at home after discharge. In addition,
the control group improved in the social and vitality domains,
and the singing group in the emotional and digestion domains of
the CFQ-R. Both groups’ improvements in some QoL domains
may be due to the standard medical treatment they received as
inpatients or the fact that they were discharged from hospital, or
a combination of both. It was not possible for this study design
to assess the impact of singing independent of this standard treat-
ment. In summary, without sufficient data, the effect of a singing
intervention onQoL for people with CF cannot be confirmed and
more studies are needed to assess possible health benefits, in light
of other studies which have indicated a positive impact of singing
on QoL (Bonilha 2009; Engen 2005; Kenny 2004; Lord 2010;
Lord 2012; Unwin 2002; Wiens 1999).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient evidence to recommend singing as an ef-
fective adjunct treatment in individuals with CF. However, peo-
ple with CF who enjoy singing should be encouraged to do so.
There is growing interest in non-medical treatments for CF, and
more research into these treatments, including singing, is needed
to inform health practitioners, people with CF and their families
(Butler 2012).
Implications for research
Adequately-powered and carefully-designed research studies are
needed. The design of future RCTs should take account of CF
severity (mild, moderate and severe), and include detailed infor-
mation about the singing intervention (vocal exercises, song type,
pitch and dynamic range); delivery format (individual or group);
length and frequency of sessions and prescribed singing practice
time. Future studies could also take account of participants’ pre-
vious experience with singing. Trials evaluating short-term (acute
admission, up to one month), medium-term (over one month and
up to six months) and longer-term outcomes (over six months and
up to one year and annually thereafter) are also required. Future
studies could also address the effects of singing for people with
advanced CF in relation to QoL.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Irons 2012
Methods A dual-centre (two paediatric hospitals in Australia), parallel, RCT; singing group versus
non-physical recreation group during hospitalisation due to a pulmonary exacerbation;
intervention duration approximately 2 weeks. Follow up 6 - 8 weeks post-intervention
Participants 51 inpatients enrolled (singing group n = 26; control group n = 25), analysed 40 at post-
intervention (singing group n = 20; control group n = 20) and 30 at follow up (singing
group n = 15; control group n = 15)
Age range: 7 - 17 years; mean (SD) age: singing group = 12.1 (3.1) years; control group
= 11.1 (3.7) years
Gender: singing group = 35% male; control group = 50% male.
Inclusion criteria: young people with an established diagnosis of CF who were being
treated as inpatients for a respiratory exacerbation
Exclusion criteria: young people who had undertaken individual singing lessons within
the past 5 years, who had an intellectual disability or who, according to their treating
physician, were too ill to participate in singing activities
Interventions Experimental (singing) group: 8 standard individual singing sessions consisting of 4-
stage program including posture, diaphragmatic breathing exercise, vocal warm-up and
singing favourite songs
Control group: 8 individual non-physical recreation sessions (e.g. playing computer
games, watching movies)
Both groups received intravenous antibiotic treatment and chest physiotherapy as the
standard hospital care
Singing and recreation session facilitator was a qualified, experienced music therapist
Post-intervention only for the singing group: a singing diary of 6 simple singing tasks
for 6 - 8 weeks
Outcomes Changes in MIP, MEP, QoL (CFQ-R), and spirometry (FEV1, FVC, FEF25−75%) from
baseline to post-intervention, and to follow up (6 - 8 weeks post-intervention)
Notes No adverse events reported. Ethics approvals obtained; informed consent by participants
and their parent/caregiver; This study was conducted as a part of the first author’s PhD
studies and she received a small amount of funding from the University of Sydney for
transport and purchasing some equipment through the Post-graduate Research Support
Scheme (PRSS) during the data collection period
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequence was computer-generated by an
external person to the study
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Irons 2012 (Continued)
Allocation concealment (selection bias) Low risk Allocation was concealed by opaque stick-
ers on the randomisation list
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and clinicians were not
blinded due to the nature of the interven-
tion
Blinding of outcome assessment (detection
bias)
Quality of life scores
High risk Person who collected the QoL data was not
blinded due to the nature of the interven-
tion
Blinding of outcome assessment (detection
bias)
Respiratory function indices
Low risk Respiratory scientists who conducted lung
function tests were blinded to the partici-
pants’ group allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition rate was relatively high (21.6%),
but similar drop-out rates in both groups
were observed. Reasons for drop-out were
stated and similar in both groups
Selective reporting (reporting bias) Low risk All planned outcome measures were re-
ported at the planned time-points
Other bias High risk Selection bias, as people with a previous
positive experience of singing more likely
to agree to enrol in the study
CF: cystic fibrosis
CFQ-R: cystic fibrosis questionnaire (revised)
FEF25−75%: mid-expiratory flow
FEV1: forced expiratory volume at one second
FVC: forced vital capacity
MEP: maximum expiratory pressure
MIP: maximum inspiratory pressure
QoL: quality of life
RCT: randomised controlled trial
SD: standard deviation
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Grasso 2000 Intervention is not singing, but using pre-recorded music during daily chest percussion routine with toddlers
Kaak 2011 Intervention is not singing, but playing the didgeridoo.
Reichardt 2011 People with CF were not included; a observational study on Hustifex®-Brummer® - a singing method specially
developed for patients with COPD
Roux 2007 Intervention is not singing, but listening to music; people with CF were not included
CF: cystic fibrosis
COPD: chronic obstructive pulmonary disorder
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D A T A A N D A N A L Y S E S
Comparison 1. Respiratory muscle strength tests
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in maximal inspiratory
pressure (cm H2O)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 short term (up to 1
month)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 medium term (> 1 month
and < 6 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Change in maximal expiratory
pressure (cm H2O)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 short term (up to 1
month)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 medium term (> 1 month
and < 6 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Spirometry
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in FEV1 (L/sec) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 short term (up to 1
month)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 medium term (> 1 month
and < 6 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Change in FVC (L) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 short term (up to 1
month)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 medium term (> 1 month
and < 6 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Change in FEF25-75% (L) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 short term (up to 1
month)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 medium term (> 1 month
and < 6 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Respiratory muscle strength tests, Outcome 1 Change in maximal inspiratory
pressure (cm H2O).
Review: Singing as an adjunct therapy for children and adults with cystic fibrosis
Comparison: 1 Respiratory muscle strength tests
Outcome: 1 Change in maximal inspiratory pressure (cm H2O)
Study or subgroup Singing Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 short term (up to 1 month)
Irons 2012 20 12.1 (9.78) 20 6.1 (14.52) 6.00 [ -1.67, 13.67 ]
2 medium term (> 1 month and < 6 months)
Irons 2012 15 12.467 (17.683) 15 8.07 (20.662) 4.40 [ -9.36, 18.16 ]
-20 -10 0 10 20
Favours control Favours singing
Analysis 1.2. Comparison 1 Respiratory muscle strength tests, Outcome 2 Change in maximal expiratory
pressure (cm H2O).
Review: Singing as an adjunct therapy for children and adults with cystic fibrosis
Comparison: 1 Respiratory muscle strength tests
Outcome: 2 Change in maximal expiratory pressure (cm H2O)
Study or subgroup Singing Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 short term (up to 1 month)
Irons 2012 20 9 (17.63) 20 5.95 (30.62) 3.05 [ -12.43, 18.53 ]
2 medium term (> 1 month and < 6 months)
Irons 2012 15 26.4 (26.532) 15 0.6 (28.908) 25.80 [ 5.94, 45.66 ]
-50 -25 0 25 50
Favours control Favours singing
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Analysis 2.1. Comparison 2 Spirometry, Outcome 1 Change in FEV1 (L/sec).
Review: Singing as an adjunct therapy for children and adults with cystic fibrosis
Comparison: 2 Spirometry
Outcome: 1 Change in FEV1 (L/sec)
Study or subgroup Singing Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 short term (up to 1 month)
Irons 2012 20 0.053 (0.21) 20 0.1 (0.28) -0.04 [ -0.20, 0.11 ]
2 medium term (> 1 month and < 6 months)
Irons 2012 15 -0.03 (0.29) 15 0.12 (0.285) -0.15 [ -0.36, 0.06 ]
-0.2 -0.1 0 0.1 0.2
Favours control Favours singing
Analysis 2.2. Comparison 2 Spirometry, Outcome 2 Change in FVC (L).
Review: Singing as an adjunct therapy for children and adults with cystic fibrosis
Comparison: 2 Spirometry
Outcome: 2 Change in FVC (L)
Study or subgroup Singing Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 short term (up to 1 month)
Irons 2012 20 0.017 (0.239) 20 0.11 (0.258) -0.10 [ -0.25, 0.06 ]
2 medium term (> 1 month and < 6 months)
Irons 2012 15 -0.045 (0.265) 15 0.06 (0.236) -0.11 [ -0.29, 0.07 ]
-0.5 -0.25 0 0.25 0.5
Favours control Favours singing
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Analysis 2.3. Comparison 2 Spirometry, Outcome 3 Change in FEF25-75% (L).
Review: Singing as an adjunct therapy for children and adults with cystic fibrosis
Comparison: 2 Spirometry
Outcome: 3 Change in FEF25−75% (L)
Study or subgroup Singing Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 short term (up to 1 month)
Irons 2012 20 0.158 (0.311) 20 0.19 (0.755) -0.03 [ -0.39, 0.33 ]
2 medium term (> 1 month and < 6 months)
Irons 2012 15 -0.017 (0.497) 15 0.27 (0.9) -0.29 [ -0.81, 0.24 ]
-1 -0.5 0 0.5 1
Favours control Favours singing
A D D I T I O N A L T A B L E S
Table 1. Glossary
Term Explanation
cough peak flow highest expiratory flow generated during a forced cough manoeuvre, measured in litre per second
visual analogue scale a response scale commonly used in questionnaires, to indicate levels of agreement or disagreement to a
statement on a continuous line, e.g. strongly disagree, disagree, agree, strongly agree
Table 2. QoL results
Domain Time Treatment group
medians (IQR)
Statistical
significance in
change from base-
line
Control group
medians (IQR)
Statistical
significance in
change from base-
line
Physical baseline 80.50 (54.1 to 88.
88)
72.21 (56.94 to 88.
80)
post-intervention 83.30 (62.48 to 93.
74)
83.30 (51.39 to 95.
46)
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Table 2. QoL results (Continued)
follow up 83.30 (70.8 to 95.
83)
91.66 (75.00 to 100.
00)
Emotional baseline 81.65 (71.46 to 87.
50)
84.97 (60.63 to 92.
88)
post-intervention 83.30 (73.73 to 92.
91)
P = 0.031 80.00 (64.58 to 91.
65)
follow up 75.00 (66.60 to 91.
60)
83.30 (66.66 to 100.
00)
Social baseline 71.42 (57.10 to 79.
76)
71.80 (61.90 to 85.
70)
post-intervention 71.81 (62.48 to 83.
30)
66.60 (54.50 to 76.
17)
P = 0.044
follow up 71.42 (66.6 to 85.
71)
72.20 (52.38 to 90.
47)
Body image baseline 83.29 (66.62 to 100.
00)
77.77 (69.42 to 100.
00)
post-intervention 94.44 (66.66 to 100.
00)
83.25 (66.66 to 97.
22)
follow up 100.00 (66.60 to
100.00)
88.80 (77.70 to 100.
00)
Eating baseline 100.00 (55.55 to
100.00)
100.00 (66.62 to
100.00)
post-intervention 88.88 (66.60 to 100.
00)
83.29 (66.62 to 100.
00)
follow up 88.88 (66.60 to 100.
00)
100.00 (88.80 to
100.00)
Treatment burden baseline 66.63 (55.50 to 77.
77)
61.08 (47.21 to 77.
70)
post-intervention 77.74 (66.62 to 97.
20)
P = 0.014 66.60 (44.44 to 94.
44)
P = 0.026
follow up 77.70 (55.50 to 100.
00)
P = 0.031 66.60 (44.40 to 77.
77)
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Table 2. QoL results (Continued)
Respiratory symp-
toms
baseline 66.60 (52.08 to 77.
03)
58.30 (50.00 to 2.
92)
post-intervention 80.54 (75.00 to 88.
80)
P = 0.001 79.15 (60.38 to 87.
43)
P = 0.002
follow up 83.30 (72.20 to 91.
66)
P = 0.016 83.30 (66.60 to 88.
80)
P = 0.013
Digestion baseline 83.33 (66.62 to 100.
00)
94.40 (66.60 to 100.
00)
post-intervention 100.00 (88.88 to
100.00)
P = 0.024 100.00 (66.62 to
100.00)
follow up 100.00 (88.80 to
100.00)
100.00 (66.66 to
100.00)
Vitality baseline 45.80 (33.32 to 54.
17)
49.95 (33.32 to 64.
55)
post-intervention 41.63 (33.30 to 66.
62)
66.65 (45.83 to 91.
60)
P = 0.043
follow up 50.00 (41.67 to 58.
33)
75.00 (49.95 to 85.
40)
Health perception baseline 61.05 (38.86 to 80.
50)
44.42 (30.53 to 80.
48)
post-intervention 61.05 (47.18 to 83.
28)
77.70 (61.06 to 100.
00)
follow up 55.50 (33.31 to 83.
29)
88.80 (58.32 to 94.
40)
Role baseline 58.33 (47.90 to 77.
08)
62.47 (54.13 to 87.
48)
post-intervention 58.30 (39.53 to 66.
62)
66.63 (58.30 to 77.
08)
follow up 75.00 (58.33 to 75.
00)
83.30 (49.95 to 95.
83)
Weight baseline 100.00 (0.00 to 100.
00)
33.30 (24.98 to 50.
00)
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Table 2. QoL results (Continued)
post-intervention 100.00 (24.98 to
100.00)
66.60 (33.32 to 100.
00)
follow up 100.00 (0.00 to 100.
00)
66.60 (33.31 to 100.
00)
IQR: inter-quartile range
A P P E N D I C E S
Appendix 1. AMED Search Strategy (searched on 24/05/2012)
AMED Search Strategy
1. exp Cystic Fibrosis/
2. Cystic Fibrosis.tw
3. CF.tw
4. Mucoviscidosis.tw
5. 1 or 2 or 3 or 4
6. Sing or Singing or Singer* or Song*.tw
7. (Vocal* or breath*) adj2 exercis*.tw
8. Choir*.tw
9. Diaphragm* adj2 breath*.tw
10. 6 or 7 or 8 or 9
11. Exp Clinical trials/
12. Clinical trial.pt
13. Random*.tw
14. Placebo.tw
15. Crossover or Cross-over.tw
16. 11 or 12 or 13 or 14 or 15
16. 5 and 10 and 16
Key
tw: textword
Exp/: exploded AMED Thesaurus term
pt: publication type
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Appendix 2. PsychINFO Search Strategy (searched on 24/05/2012)
PsycINFO Search Strategy via OvidSP
1. Cystic Fibrosis/ [PsyINFO Thesaurus Descriptor]
2. Cystic Fibrosis [keyword]
3. CF [keyword]
4. Mucoviscidosis [keyword]
5. 1 or 2 or 3 or 4
6. Sing or Singing or Singer* or Song* [keyword]
7. (Vocal* or breath*) adj2 exercis*[keyword]
8. Choir*[keyword]
9. Diaphragm* adj2 breath* [keyword]
10. 6 or 7 or 8 or 9
11. Clinical trials [PsychINFO Thesaurus Descriptor]
12. Random* [keyword]
13. Placebo.tw [keyword]
14. Crossover or Cross-over [keyword]
15. 11 or 12 or 13 or 14
16. 5 and 10 and 15
Appendix 3. CINAHL Search Strategy (searched on 24/05/2012)
CINAHL Search Strategy via EBSCO
1. (MH “Cystic Fibrosis”) [CINAHL Subject Heading]
2. Cystic Fibrosis [all text]
3. CF [all text]
4. Mucoviscidosis [all text]
5. 1 or 2 or 3 or 4
6. Sing or Singing or Singers or Song* [all text]
7. (Vocal* or breath*) adj2 exercis* [all text]
8. Choir* [all text]
9. Diaphragm* adj2 breath* [all text]
10. 6 or 7 or 8 or 9
11. (MH “Clinical Trials+”) [Exploded CINAHL Subject heading]
12. Clinical trial [publication type]
13. Random* [all text]
14. Placebo [all text]
15. Crossover or Cross-over [all text]
16. 11 or 12 or 13 or 15
17. 5 and 10 and 16
27Singing as an adjunct therapy for children and adults with cystic fibrosis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 4. ProQuest Search Strategy: Dissertation Abstracts International (late 1960 to present)
(searched on 25/05/2012)
ProQuest Search Strategy: Dissertation Abstracts International (late 1960 to present)
1. [as key words in citation and abstract] Cystic fibrosis
2. [as key words in citation and abstract] Cystic fibrosis AND Breathing
3. [as key words in citation and abstract] Cystic fibrosis AND Voice
4. [as key words in citation and abstract] Cystic fibrosis AND music
5. [as key words in citation and abstract] Cystic fibrosis AND singing
6. [as key words in citation and abstract] Music therapy AND breathing
7. [as key words in citation and abstract] Singing AND breathing
8. [as key words in citation and abstract] singing OR breathing exercise AND respiratory
9. [as key words in citation and abstract] choir AND effect
Appendix 5. Clinicaltrials.gov Search Strategy (searched on 25/5/2012)
Clinicaltrials.gov Search Strategy
Advanced Search
Condition: Cystic Fibrosis
Interventions: sing/singing/singer/song/diaphragmatic/vocal/choir
Appendix 6. Music therapy research database (www.musictherapyworld.de) Search Strategy
(searched on 24/09/2009)
Music therapy research database (www.musictherapyworld.de) Search Strategy
No electronic search was possible using search terms. Thus, all abstracts were reviewed
1. Dissertations on Music Therapy (1994 - 2006)
2. Conference Reports Archive (1993 - 2001)
Appendix 7. National Research Register Archive Search Strategy (2000 - 2012)
28Singing as an adjunct therapy for children and adults with cystic fibrosis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
National Research Register Archive Search Strategy
cystic fibrosis AND sing OR singing OR breathing OR choir OR vocal
WH A T ’ S N E W
Last assessed as up-to-date: 31 March 2014.
Date Event Description
13 April 2015 Amended Contact details updated.
H I S T O R Y
Protocol first published: Issue 4, 2009
Review first published: Issue 5, 2010
Date Event Description
31 March 2014 New citation required and conclusions have changed The previously ongoing study has been completed and
results have been added to this review (Irons 2012). While
no meta-analysis was possible since there is only one study
included, we have presented results in forest plots where
available
31 March 2014 New search has been performed A search of theGroup’s Cystic Fibrosis Trials Register iden-
tified no new reference potentially eligible for inclusion in
this review. New searches including hand searching iden-
tified no new eligible studies to be included for this review
C O N T R I B U T I O N S O F A U T H O R S
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Protocol stage: draft the protocol JY Irons, AB Chang, DT Kenny
Review stage: select which trials to include (2 + 1 arbiter) JY Irons, AB Chang + DT Kenny
Review stage: draft the final review JY Irons, AB Chang, DT Kenny
Update stage: update the review JY Irons, AB Chang, P Petocz
D E C L A R A T I O N S O F I N T E R E S T
The authors of the original review have conducted the only trial included in this review - a randomised controlled trial with inpatients
with CF. Clinical trial registration (ACTRN 12609000471280).
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• NHMRC, Australia.
AC is supported by an NHMRC practitioner fellowship (grant number 545216)
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In a post hoc change, the authors considered that reporting the differences (change scores) from baseline to post-intervention or follow
up, or both, in the outcome measures to be appropriate in this review.
In order to assess possible adverse effects from both treatment and control interventions “Adverse effects of the intervention” has been
changed into “Adverse effects”.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Music Therapy; Cystic Fibrosis [∗therapy]
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MeSH check words
Adolescent; Adult; Child; Humans
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